TG Therapeutics, Inc. (TGTX) is a Biotechnology company in the Healthcare sector, currently trading at $34.60. It has a SharesGrow Score of 84/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TGTX = $69.05 (+99.6% from the current price, the stock appears undervalued). Analyst consensus target is TGTX = $39 (+12.7% upside).
Valuation: TGTX trades at a trailing Price-to-Earnings (P/E) of 10.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.17.
Financials: revenue is $616M, +2806%/yr average growth. Net income is $447M, growing at +667.7%/yr. Net profit margin is 72.6% (strong). Gross margin is 83.6% (-6.9 pp trend).
Balance sheet: total debt is $261M against $648M equity (Debt-to-Equity (D/E) ratio 0.4, conservative). Current ratio is 4.1 (strong liquidity). Debt-to-assets is 24.5%. Total assets: $1.1B.
Analyst outlook: 11 / 13 analysts rate TGTX as buy (85%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 100/100 (Pass), Past 75/100 (Partial), Health 83/100 (Pass), Moat 55/100 (Partial), Future 82/100 (Pass), Income 100/100 (Pass).
